David M Lonard

6PUBLICATIONS
26CO-AUTHORS
Molecular targetsPsychosocial aspects of childbirth and perinatal mental healthTumour immunologyChemical engineering designChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge.

Christopher F Bassil, Kerry Dillon, Gray R Anderson

|Jul 11, 2025
Human Extravillous Trophoblasts Require SRC-2 for Sustained Viability, Migration, and Invasion.

Vineet K Maurya, Pooja Popli, Bryan C Nikolai

|Nov 14, 2023
Steroid receptor coactivator-2 drives epithelial reprogramming that enables murine embryo implantation.

Vineet K Maurya, Maria M Szwarc, David M Lonard

|May 30, 2023
Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion.

Sang Jun Han, Prashi Jain, Yosef Gilad

|Aug 19, 2022
Reply to: Target expression is a relevant factor in synthetic lethal screens.

Yosi Gilad, Yossi Eliaz, Yang Yu

|Feb 10, 2021
Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations.

Yosi Gilad, Gary Gellerman, David M Lonard

Pageof 1

Frequent Collaborators

3 joint publications

Bert W O'Malley

2 joint publications

Sang Jun Han

2 joint publications

Li Qin

1 joint publications

Gary Gellerman